Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
7.92
-0.05 (-0.63%)
At close: Jul 21, 2025, 4:00 PM
8.06
+0.14 (1.77%)
After-hours: Jul 21, 2025, 6:50 PM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Amneal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $11.5, which forecasts a 45.2% increase in the stock price over the next year. The lowest target is $11 and the highest is $12.
Price Target: $11.5 (+45.2%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2025.
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +38.89% | Mar 3, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $9 → $12 | Hold → Buy | Upgrades | $9 → $12 | +51.52% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | +38.89% | Nov 11, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +51.52% | Oct 2, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $9 | Sell → Hold | Upgrades | $9 | +13.64% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
3.07B
from 2.79B
Increased by 9.95%
Revenue Next Year
3.32B
from 3.07B
Increased by 8.14%
EPS This Year
0.72
from -0.38
EPS Next Year
0.84
from 0.72
Increased by 17.38%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.2B | 3.5B | 3.8B |
| Avg | 3.1B | 3.3B | 3.6B |
| Low | 2.9B | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.6% | 14.1% | 15.9% |
| Avg | 10.0% | 8.1% | 7.9% |
| Low | 5.3% | -0.0% | -3.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.77 | 0.90 | 1.14 |
| Avg | 0.72 | 0.84 | 1.05 |
| Low | 0.68 | 0.76 | 0.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 25.6% | 35.6% |
| Avg | - | 17.4% | 24.1% |
| Low | - | 6.3% | 8.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.